Data / Form D filings / APOLLO ENDOSURGERY US INC
APOLLO ENDOSURGERY US INC: Form D filings
APOLLO ENDOSURGERY US INC, a biotechnology company in Austin, TX, filed 5 Form D notices with the SEC between 2009 and 2017. The latest, on January 11, 2017, reports $54.4 million sold of a $54.4 million offering to 15 investors.
Find out what APOLLO ENDOSURGERY US INC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1120 SOUTH CAPITAL OF TX HWY, BUILDING 1 SUITE 300, Austin, TX, 78746
- Phone
- (512) 279-5100
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1369432
The full lists. Form D filings in Texas: 4,800 rows, $128, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 11, 2017 | New notice | $54,432,580 | $54,432,580 | $0 | 15 | Dec 29, 2016 | sec.gov |
| Dec 16, 2013 | New notice | $63,727,392 | $60,727,392 | $3,000,000 | 11 | Dec 2, 2013 | sec.gov |
| Jul 3, 2013 | New notice | $11,603,494 | $5,044,998 | $6,558,496 | 8 | Jun 18, 2013 | sec.gov |
| Feb 10, 2012 | New notice | $53,835,471 | $52,724,242 | $1,111,229 | 14 | Oct 25, 2011 | sec.gov |
| Mar 23, 2009 | New notice | $3,166,170 | $3,000,000 | $166,170 | 2 | Mar 6, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Bruce Robertson, Ph.D. | Director | |
| Richard Meelia | Director | |
| John Creecy | Director | |
| William McClellan, Jr. | Director | |
| Matthew Crawford | Director | |
| Charles Tribie | Executive Officer | |
| Todd Newton | Executive Officer, Director | |
| Stefanie Cavanaugh | Executive Officer | |
| R. Kent McGaughy, Jr. | Director | |
| Bret Schwartzhoff | Executive Officer | |
| Jack Nielsen | Director | |
| Rick Anderson | Director | |
| Dennis McWilliams | Executive Officer |
Other biotechnology companies in Texas that filed recently
- Nuclein, LLC $15.7 million · Oct 27, 2026
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
Every Form D from the week of Jan 9, 2017 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what APOLLO ENDOSURGERY US INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.